189 related items for PubMed ID: 25142334
21. Urinary soluble HLA class I antigen in patients with minimal change disease: a predictor of steroid response.
Park CW, Song HC, Shin YS, Ahn SJ, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK.
Nephron; 1998; 79(1):44-9. PubMed ID: 9609461
[Abstract] [Full Text] [Related]
22. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G.
Am J Physiol Renal Physiol; 2016 Mar 01; 310(5):F335-41. PubMed ID: 26697986
[Abstract] [Full Text] [Related]
23. Urinary CD80 and Serum suPAR as Biomarkers of Glomerular Disease among Adults in Brazil.
Zen RC, Dominguez WV, Braga I, Dos Reis LM, Jorge LB, Yu L, Woronik V, Dias CB.
Diagnostics (Basel); 2023 Jan 05; 13(2):. PubMed ID: 36673014
[Abstract] [Full Text] [Related]
24. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.
Ramezani A, Devaney JM, Cohen S, Wing MR, Scott R, Knoblach S, Singhal R, Howard L, Kopp JB, Raj DS.
Eur J Clin Invest; 2015 Apr 05; 45(4):394-404. PubMed ID: 25682967
[Abstract] [Full Text] [Related]
25. Urinary Exosomal miR-193a Can Be a Potential Biomarker for the Diagnosis of Primary Focal Segmental Glomerulosclerosis in Children.
Huang Z, Zhang Y, Zhou J, Zhang Y.
Biomed Res Int; 2017 Apr 05; 2017():7298160. PubMed ID: 28246603
[Abstract] [Full Text] [Related]
26. Cytotoxic T- Lymphocyte Antigen-4 (CTLA4) Gene Expression and Urinary CTLA4 Levels in Idiopathic Nephrotic Syndrome.
Mishra OP, Chhabra P, Narayan G, Srivastava P, Prasad R, Singh A, Abhinay A, Batra VV.
Indian J Pediatr; 2019 Jan 05; 86(1):26-31. PubMed ID: 29968132
[Abstract] [Full Text] [Related]
27. Proteomic profile‑based screening of potential protein biomarkers in the urine of patients with nephrotic syndrome.
Wang Y, Zheng C, Wang X, Zuo K, Liu Z.
Mol Med Rep; 2017 Nov 05; 16(5):6276-6284. PubMed ID: 28849145
[Abstract] [Full Text] [Related]
28. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice.
Ishimoto T, Shimada M, Gabriela G, Kosugi T, Sato W, Lee PY, Lanaspa MA, Rivard C, Maruyama S, Garin EH, Johnson RJ.
Nephrol Dial Transplant; 2013 Jun 05; 28(6):1439-46. PubMed ID: 23262434
[Abstract] [Full Text] [Related]
29. Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes.
Ishimoto T, Cara-Fuentes G, Wang H, Shimada M, Wasserfall CH, Winter WE, Rivard CJ, Araya CE, Saleem MA, Mathieson PW, Johnson RJ, Garin EH.
Pediatr Nephrol; 2013 Sep 05; 28(9):1803-12. PubMed ID: 23689904
[Abstract] [Full Text] [Related]
30. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis.
Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, D'Amico G.
Nephrol Dial Transplant; 2002 Nov 05; 17(11):1890-6. PubMed ID: 12401843
[Abstract] [Full Text] [Related]
31. Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis.
An JN, Hyeon JS, Jung Y, Choi YW, Kim JH, Yang SH, Oh S, Kwon S, Lee SH, Cho JH, Park SH, Ha H, Kim DK, Lee JP, Hwang GS.
Sci Rep; 2019 Oct 11; 9(1):14707. PubMed ID: 31605028
[Abstract] [Full Text] [Related]
32. [The clinic significance of urinary podocytes in patients with focal segmental glomerulosclerosis].
Li YH, Huang HC, Liu G, Zhang YK.
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr 11; 36(2):135-8. PubMed ID: 15100729
[Abstract] [Full Text] [Related]
33. CD80 and CTLA-4 as diagnostic and prognostic markers in adult-onset minimal change disease: a retrospective study.
Zhao B, Han H, Zhen J, Yang X, Shang J, Xu L, Wang R.
PeerJ; 2018 Apr 11; 6():e5400. PubMed ID: 30083478
[Abstract] [Full Text] [Related]
34. Maximal 'CD80-uria' with minimal change.
Kistler AD, Reiser J.
Kidney Int; 2010 Aug 11; 78(3):236-8. PubMed ID: 20631735
[Abstract] [Full Text] [Related]
35. Urinary peptide profiling to differentiate between minimal change disease and focal segmental glomerulosclerosis.
Pérez V, Ibernón M, López D, Pastor MC, Navarro M, Navarro-Muñoz M, Bonet J, Romero R.
PLoS One; 2014 Aug 11; 9(1):e87731. PubMed ID: 24498182
[Abstract] [Full Text] [Related]
36. CD80 and suPAR: diagnostic and pathogenic value in minimal change disease and focal segmental glomerulosclerosis?
Davin JC.
Pediatr Nephrol; 2014 Aug 11; 29(8):1465-6. PubMed ID: 24839215
[No Abstract] [Full Text] [Related]
37. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.
Hansrivijit P, Puthenpura MM, Ghahramani N.
Clin Nephrol; 2020 Sep 11; 94(3):117-126. PubMed ID: 32589135
[Abstract] [Full Text] [Related]
38. Immunoglobulin G/albumin staining in tubular protein reabsorption droplets in minimal change disease and focal segmental glomerulosclerosis.
Bu L, Mirocha J, Haas M.
Nephrol Dial Transplant; 2021 May 27; 36(6):1016-1022. PubMed ID: 32191308
[Abstract] [Full Text] [Related]
39. Systematic biomarker discovery and coordinative validation for different primary nephrotic syndromes using gas chromatography-mass spectrometry.
Lee JE, Lee YH, Kim SY, Kim YG, Moon JY, Jeong KH, Lee TW, Ihm CG, Kim S, Kim KH, Kim DK, Kim YS, Kim CD, Park CW, Lee do Y, Lee SH.
J Chromatogr A; 2016 Jul 01; 1453():105-15. PubMed ID: 27247212
[Abstract] [Full Text] [Related]
40. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance: response.
Cara-Fuentes G, Johnson RJ, Reiser J, Garin EH.
Pediatr Nephrol; 2014 Aug 01; 29(8):1467-8. PubMed ID: 24817342
[No Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
